Pancreatic Cancer Research

ResearcherPhilipps University of MarburgActive in the last 2 years

Patrick Michl

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0401-5600; OpenAlex author ID A5023460203. Sources: OpenAlex.

Their work

Papers
43 (first author 5, last author 8)
Trials
0
Grants
0
Labs led
2
Collaborators
165
Papers, trials and grants by year

2011: 1 paper · 2012: 4 papers · 2013: 8 papers · 2014: 3 papers · 2015: none · 2016: 2 papers · 2017: 3 papers · 2018: 2 papers · 2019: 1 paper · 2020: 3 papers · 2021: 5 papers · 2022: 2 papers · 2023: 2 papers · 2024: 4 papers · 2025: 1 paper · 2026: 2 papers

Papers 43

  1. Pathophysiology, assessment, and treatment of pain in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00535-026-02423-3↗
  2. Seeing the unseen: AI radiomics unmasking occult pancreatic cancer? Co-author DOI 10.1136/gutjnl-2026-338712↗
  3. Trends in the Treatment and Survival of Pancreatic Cancer: Analysis of 23,339 Patients Diagnosed Between 2010 and 2017. Co-author DOI 10.1002/cam4.71248↗
  4. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pan… Co-author DOI 10.1016/s2468-1253(24)00197-3↗
  5. Quantitative Metabolomics and Lipoprotein Analysis of PDAC Patients Suggests Serum Marker Categories for Pancreatic Function, Pancreatectomy, Cancer Metabolism… Co-author DOI 10.1021/acs.jproteome.3c00611↗
  6. Induction of oxidative- and endoplasmic-reticulum-stress dependent apoptosis in pancreatic cancer cell lines by DDOST knockdown. Co-author DOI 10.1038/s41598-024-68510-8↗
  7. Female advantage in neoadjuvant pancreatic cancer therapy: is it down to macrophages? Co-author DOI 10.1136/gutjnl-2023-330830↗
  8. Body composition parameters predict survival in pancreatic cancer-A retrospective multicenter analysis. Co-author DOI 10.1002/ueg2.12489↗
  9. Gender-specific changes of the gut microbiome correlate with tumor development in murine models of pancreatic cancer. Co-author DOI 10.1016/j.isci.2023.106841↗
  10. Discussion: Current Multimodality Treatment Options in Pancreatic Cancer in Clinical Practice - What Is the Future Impact of Molecular Biological Profiling? Co-author DOI 10.1159/000521847↗
  11. Pancreatic Cancer From the Patient Perspective: The Time to Act is Now. First author DOI 10.1177/23743735221112633↗
  12. UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better. Co-author DOI 10.1002/ueg2.12123↗
  13. New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Co-author DOI 10.1053/j.gastro.2021.04.082↗
  14. Pre-operative/Neoadjuvant Therapy and Vascular Debranching Followed by Resection for Locally Advanced Pancreatic Cancer (PREVADER): Clinical Feasibility Trial. Co-author DOI 10.3389/fmed.2021.588375↗
  15. CUX1 Enhances Pancreatic Cancer Formation by Synergizing with KRAS and Inducing MEK/ERK-Dependent Proliferation. Last author DOI 10.3390/cancers13102462↗
  16. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta… Co-author DOI 10.3390/cancers13174326↗
  17. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Last author DOI 10.1016/j.pan.2020.06.012↗
  18. The quality of pain management in pancreatic cancer: A prospective multi-center study. Co-author DOI 10.1016/j.pan.2020.08.017↗
  19. RNA Binding Proteins as Drivers and Therapeutic Target Candidates in Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/ijms21114190↗
  20. Stromal biology and therapy in pancreatic cancer: ready for clinical translation? Co-author DOI 10.1136/gutjnl-2018-316451↗
  21. Therapeutic developments in pancreatic cancer: current and future perspectives. Co-author DOI 10.1038/s41575-018-0005-x↗
  22. Overcoming immune evasion in pancreatic cancer: the combination matters. Co-author DOI 10.1136/gutjnl-2017-315443↗
  23. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Co-author DOI 10.1007/s11523-016-0469-y↗
  24. Targeted therapy of pancreatic cancer: biomarkers are needed. First author DOI 10.1016/s1470-2045(17)30087-6↗
  25. Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer. Last author DOI 10.1136/gutjnl-2015-310049↗
  26. miRNA dynamics in tumor-infiltrating myeloid cells modulating tumor progression in pancreatic cancer. Last author DOI 10.1080/2162402x.2016.1160181↗
  27. DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-016-2052-4↗
  28. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice. Co-author DOI 10.1053/j.gastro.2014.08.002↗
  29. nab-Paclitaxel: novel clinical and experimental evidence in pancreatic cancer. First author DOI 10.1055/s-0034-1366002↗
  30. Desmoplasia and chemoresistance in pancreatic cancer. Co-author DOI 10.3390/cancers6042137↗
  31. [nab-Paclitaxel as new therapeutic option for pancreatic cancer]. Co-author DOI 10.1055/s-0033-1350545↗
  32. [S3-guideline exocrine pancreatic cancer]. Co-author DOI 10.1055/s-0033-1356220↗
  33. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Co-author DOI 10.1093/annonc/mdt270↗
  34. Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions. Last author DOI 10.1136/gutjnl-2012-302577↗
  35. Current concepts and novel targets in advanced pancreatic cancer. Co-author DOI 10.1136/gutjnl-2012-303588↗
  36. WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer. Last author DOI 10.1593/neo.121312↗
  37. Synthetic lethality screen identifies RPS6KA2 as modifier of epidermal growth factor receptor activity in pancreatic cancer. Last author DOI 10.1593/neo.131660↗
  38. Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Co-author DOI 10.2147/ott.s38111↗
  39. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. Co-author DOI 10.1093/annonc/mdr351↗
  40. Targeting cathepsins: a new glimmer of hope for pancreatic cancer therapy? Co-author DOI 10.1136/gutjnl-2011-301816↗
  41. Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid. Co-author DOI 10.1136/gutjnl-2012-302604↗
  42. Therapeutic targeting of apoptotic pathways: novel aspects in pancreatic cancer. Last author DOI 10.2174/138920112802501953↗
  43. Stromal biology and therapy in pancreatic cancer. First author DOI 10.1136/gut.2010.226092↗

Closest collaborators

The 25 strongest of 165 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jonas Rosendahl · 8 shared papers, 2017–2025 · strength 1.25
  2. Sebastian Krug · 9 shared papers, 2013–2025 · strength 1.23
  3. Laura Roth · 2 shared papers, 2024–2026 · strength 1.09
  4. Marko Damm · 6 shared papers, 2020–2026 · strength 1.07
  5. Thomas Mathias Gress · 15 shared papers, 2011–2021 · strength 0.80
  6. Jorg H. Kleeff · 4 shared papers, 2017–2021 · strength 0.53
  7. Heidi Griesmann · 7 shared papers, 2013–2023 · strength 0.53
  8. Matthias J. Löhr · 4 shared papers, 2014–2022 · strength 0.41
  9. Volker Ellenrieder · 4 shared papers, 2013–2022 · strength 0.36
  10. Albrecht Neeße · 6 shared papers, 2011–2019 · strength 0.32
  11. Bence Sipos · 4 shared papers, 2013–2021 · strength 0.30
  12. Marie-Theres Kassik · 1 shared paper, 2026 · strength 0.28
  13. Asbjørn Mohr Drewes · 1 shared paper, 2026 · strength 0.28
  14. Vikesh K. Singh · 1 shared paper, 2026 · strength 0.28
  15. Mahya Faghih · 1 shared paper, 2026 · strength 0.28
  16. Søren Schou Olesen · 1 shared paper, 2026 · strength 0.28
  17. Michael Hirth · 1 shared paper, 2026 · strength 0.28
  18. David Arthur Tuveson · 5 shared papers, 2011–2019 · strength 0.27
  19. Alexander Kleger · 2 shared papers, 2021–2022 · strength 0.26
  20. John P. Neoptolemos · 3 shared papers, 2012–2021 · strength 0.26
  21. Maximilian Reichert · 2 shared papers, 2021–2024 · strength 0.25
  22. Stefan Hubert Boeck · 2 shared papers, 2020–2024 · strength 0.24
  23. Malte Buchholz · 5 shared papers, 2011–2019 · strength 0.22
  24. Richard Böhme · 1 shared paper, 2024 · strength 0.22
  25. Thomas Jens Ettrich · 2 shared papers, 2016–2024 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.